Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy

Iantrek筹集4200万美元C轮融资，推出突破性青光眼介入疗法AlloFlo™ Uveo

New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathway

随着资金推动对葡萄膜巩膜通路的手术访问，数百万青光眼患者迎来新希望。

WHITE PLAINS, N.Y., August 20, 2025-- Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C financing round, which will fund the U.S. commercial launch of AlloFlo™ Uveo, a first-of-its-kind surgical solution targeting the uveoscleral pathway, as well as broader pipeline expansion.

纽约州怀特普莱恩斯，2025年8月20日——生物介入性眼科手术（BIOS）领域的先驱Iantrek公司今天宣布完成了4200万美元的C轮融资。这笔资金将用于在美国市场推出AlloFlo™ Uveo，这是一种针对葡萄膜巩膜通路的首创手术解决方案，同时也将推动更广泛的产品线扩展。

The Series C was led by U.S. Venture Partners (USVP), joined by aMoon Fund, along with existing investors Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures..

C轮融资由美国风险合伙人（USVP）领投，aMoon基金加入，现有投资者Visionary Ventures、Sectoral Asset Management、Radius Special Situations Fund和Civilization Ventures也参与其中。

“Our mission is to address a major unmet need in glaucoma care, and this fundraise marks a pivotal moment in helping us achieve it,” said Adam Szaronos, CEO of Iantrek. “More than 2.5 million eyes in the U.S. are experiencing waning efficacy from previous Minimally Invasive Glaucoma Surgery (MIGS) procedures targeting the trabecular pathway.

“我们的使命是解决青光眼护理中一个重要的未满足需求，而此次融资标志着我们实现这一目标的关键时刻，”Iantrek首席执行官Adam Szaronos表示。“美国有超过250万只眼睛因之前针对小梁通路的微创青光眼手术（MIGS）效果减弱而受到影响。”

AlloFlo™ Uveo enables access to the uveoscleral pathway, the eye’s other natural drainage system—much like giving a thoracic surgeon the ability to enhance the second lung.”.

AlloFlo™ Uveo 能够进入葡萄膜巩膜通路，这是眼睛的另一个天然引流系统——就像赋予胸外科医生增强第二肺的能力一样。

Unlocking the Other Half of the Eye’s Drainage System

解锁眼睛引流系统的另一半

Glaucoma is a chronic, vision-threatening disease that causes irreversible damage to the optic nerve. Glaucoma management generally involves reducing intraocular pressure (IOP) by increasing aqueous drainage or decreasing aqueous production. In healthy eyes, two distinct outflow pathways regulate aqueous drainage: the trabecular and the uveoscleral.

青光眼是一种慢性、威胁视力的疾病，会对视神经造成不可逆的损伤。青光眼的治疗通常涉及通过增加房水引流或减少房水生成来降低眼内压 (IOP)。在健康的眼睛中，有两种不同的引流途径调节房水排出：小梁网和葡萄膜巩膜途径。

While existing MIGS devices focus exclusively on the trabecular outflow pathway, Iantrek’s BIOS platform introduces a breakthrough in minimally invasive access to the uveoscleral pathway—a route long targeted by pharmaceuticals but, until now, lacked technological options to enhance surgically..

现有的MIGS设备仅专注于小梁网流出通道，而Iantrek的BIOS平台在微创进入葡萄膜巩膜通路方面实现了突破——这一通路长期以来是药物治疗的目标，但直到现在仍缺乏通过手术增强的技术选项。

“This raise reflects strong confidence in Iantrek’s bold vision and disruptive approach to interventional glaucoma,” said Casey Tansey, General Partner at USVP. “Their platform is redefining what’s possible by combining simplicity, precision, and improved outcomes.”

“这次融资反映了对Iantrek大胆愿景和在干预性青光眼领域的颠覆性方法的强烈信心，”美国风险投资公司（USVP）的普通合伙人凯西·坦西表示。“他们的平台通过结合简便性、精确性和改善的结果，重新定义了可能性。”

Clinical Evidence and Early Adoption

临床证据与早期应用

In 2025, the American Academy of Ophthalmology published a peer-reviewed study in Ophthalmology Science demonstrating long-term efficacy and safety in patients having undergone bio-reinforced cyclodialysis with AlloFlo Uveo. Key findings after 2 years included a mean reduction of intraocular pressures (IOP) of 34%, use of IOP-lowering medications decreased by >60%, and no serious product-related adverse events reported.¹.

2025年，美国眼科学会于《眼科科学》期刊发布了一项经过同行评议的研究，证明了接受AlloFlo Uveo生物增强睫状体分离术的患者在长期疗效和安全性方面的表现。两年后的关键研究结果显示，平均眼内压（IOP）降低了34%，降眼压药物的使用减少了60%以上，且无严重与产品相关的不良事件报告。¹

“With approximately 3,000 procedures performed through its early access program, surgeon demand for uveoscleral pathway access is clear,” said Sean Ianchulev, MD, MPH, Professor of Ophthalmology at the New York Eye and Ear of Mount Sinai and Chairman of the Board of Iantrek.

“通过其早期访问计划，已经进行了约3000例手术，外科医生对葡萄膜巩膜通路的需求显而易见，”医学博士、公共卫生硕士肖恩·扬丘列夫说道，他是西奈山纽约眼耳医院的眼科教授，同时也是Iantrek公司的董事会主席。

“Iantrek’s bio-interventional approach is currently the only surgical solution targeting this major outflow pathway with the highest therapeutic index in glaucoma treatment.”

“目前，Iantrek的生物干预方法是唯一针对青光眼治疗中这一主要流出途径且具有最高治疗指数的手术解决方案。”

Looking Ahead

展望未来

Iantrek’s portfolio includes AlloFlo™ Uveo, AlloSert™ Uveo, and C.Rex™—next-generation bio- interventional and micro-interventional solutions designed to improve surgical precision, and access to the eye’s natural outflow pathways. AlloFlo™ Uveo is the first allogeneic graft tailored for durable implantation and bio-integration in ophthalmic applications.

Iantrek的产品组合包括AlloFlo™ Uveo、AlloSert™ Uveo和C.Rex™——这些是下一代生物介入和微型介入解决方案，旨在提高手术精度以及对眼睛自然流出通道的访问。AlloFlo™ Uveo是首个专为眼科应用设计的耐用植入和生物整合的同种异体移植物。

The company has also completed first-in-human trials for its next bio-interventional product, with commercial launch expected in 2026..

该公司还完成了其下一个生物介入产品的人体首次试验，预计将于2026年上市。

“Iantrek’s sophisticated solution delivers significant clinical value and provides a new minimally invasive option for patients with glaucoma,” said Todd Sone, General Partner at aMoon Fund. “We are looking forward to working with Adam Szaronos, Dr. Sean Ianchulev, and the whole team on their mission to provide next-generation glaucoma treatment to the many thousands of patients in need.”.

“眼创公司的先进解决方案提供了显著的临床价值，并为青光眼患者提供了一种新的微创选择，”aMoon基金的普通合伙人托德·索内表示。“我们期待与亚当·萨拉诺什、肖恩·扬丘列夫博士及整个团队合作，致力于为数以万计有需要的患者提供下一代青光眼治疗。”

About Iantrek, Inc.

关于Iantrek公司

Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The company’s portfolio includes AlloSert™ Uveo, AlloFlo™ Uveo, CanaloFlo™, and C.Rex™— bio-interventional and micro-interventional solutions for the management of glaucoma.

由眼科创新者 Sean Ianchulev（医学博士、公共卫生硕士）创立的 Iantrek 是一家风险投资支持的医疗技术公司，专注于开发眼科手术用的生物介入和微型介入产品。公司产品组合包括 AlloSert™ Uveo、AlloFlo™ Uveo、CanaloFlo™ 和 C.Rex™——用于青光眼管理的生物介入和微型介入解决方案。

For more information, visit iantrekmed.com..

欲了解更多信息，请访问iantrekmed.com。

1. Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement. Calvo, Ernesto et al. Ophthalmology Science, Volume 5, Issue 4, 100727

1. 生物干预性葡萄膜巩膜外流增强手术治疗原发性开角型青光眼：使用巩膜同种移植物加固的环拨术2年结果。Calvo, Ernesto 等。《眼科科学》，第5卷，第4期，100727。

Contact:

联系人：

Media Contact:

媒体联系人：

Amy Phillips

艾米·菲利普斯

amyphillipspr@gmail.com

艾米菲利普斯公关@gmail.com

412-327-9499

412-327-9499